Nektar Therapeutics traded at $57.06 this Friday September 25th, decreasing $2.32 or 3.91 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics lost 22.65 percent. Over the last 12 months, its price fell by 2.46 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 65.66 by the end of this quarter and at 61.51 in one year, according to Trading Economics global macro models projections and analysts expectations.
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.